Logo

Agouron Will Establish Division for Oncology

Nov 14, 1998
Premium

LA JOLLA, Calif.--Agouron Pharmaceuticals announced its intention to create a separate operating division in which the company's research and development of products for oncology and related fields will be conducted. Under the proposed plan, yet to be approved by shareholders, financial performance of the oncology R&D division would be tracked as separate equity.

Agouron also announced fiscal 1998 net income of $13,154,000, or 40 cents per share, on total revenues of $466,505,000.

Filed under

Informatics
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.